Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment

DIJON, France--(BUSINESS WIRE)--ONCODESIGN (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, announced today the signing of an agreement with Eisai Inc. Oncodesign will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign’s patient-derived xenograft models (PDX) to investigate the potential of eribulin mesylate (“eribulin”) in earlier line treatment of metastatic breast cancer.

Help employers find you! Check out all the jobs and post your resume.